NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism

Motoaki Komatsu, Takeshi Kanda, Hidenori Urai, Arata Kurokochi, Rina Kitahama, Shuhei Shigaki, Takashi Ono, Hideo Yukioka, Kazuhiro Hasegawa, Hirobumi Tokuyama, Hiroshi Kawabe, Shu Wakino, Hiroshi Itoh

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nicotinamide N-methyltransferase (NNMT) catalyses the reaction between nicotinamide (NAM) and S-adenosylmethionine to produce 1-methylnicotinamide and S-adenosylhomocysteine. Recently, this enzyme has also been reported to modulate hepatic nutrient metabolism, but its role in the liver has not been fully elucidated. We developed transgenic mice overexpressing NNMT to elucidate its role in hepatic nutrient metabolism. When fed a high fat diet containing NAM, a precursor for nicotinamide adenine dinucleotide (NAD)+, these NNMT-overexpressing mice exhibit fatty liver deterioration following increased expression of the genes mediating fatty acid uptake and decreased very low-density lipoprotein secretion. NNMT overactivation decreased the NAD+ content in the liver and also decreased gene activity related to fatty acid oxidation by inhibiting NAD+-dependent deacetylase Sirt3 function. Moreover, the transgenic mice showed liver fibrosis, with the induction of inflammatory and fibrosis genes. Induced NNMT expression decreased the tissue methylation capacity, thereby reducing methylation of the connective tissue growth factor (CTGF) gene promoter, resulting in increased CTGF expression. These data indicate that NNMT links the NAD+ and methionine metabolic pathways and promotes liver steatosis and fibrosis. Therefore, targeting NNMT may serve as a therapeutic strategy for treating fatty liver and fibrosis.

Original languageEnglish
Article number8637
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Nicotinamide N-Methyltransferase
Fatty Liver
NAD
Liver Diseases
Liver Cirrhosis
Connective Tissue Growth Factor
Niacinamide
Liver
Methylation
Transgenic Mice
Fatty Acids
S-Adenosylhomocysteine
Genes
Food
S-Adenosylmethionine
VLDL Lipoproteins
High Fat Diet
Metabolic Networks and Pathways
Methionine
Fibrosis

ASJC Scopus subject areas

  • General

Cite this

NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism. / Komatsu, Motoaki; Kanda, Takeshi; Urai, Hidenori; Kurokochi, Arata; Kitahama, Rina; Shigaki, Shuhei; Ono, Takashi; Yukioka, Hideo; Hasegawa, Kazuhiro; Tokuyama, Hirobumi; Kawabe, Hiroshi; Wakino, Shu; Itoh, Hiroshi.

In: Scientific Reports, Vol. 8, No. 1, 8637, 01.12.2018.

Research output: Contribution to journalArticle

Komatsu, Motoaki ; Kanda, Takeshi ; Urai, Hidenori ; Kurokochi, Arata ; Kitahama, Rina ; Shigaki, Shuhei ; Ono, Takashi ; Yukioka, Hideo ; Hasegawa, Kazuhiro ; Tokuyama, Hirobumi ; Kawabe, Hiroshi ; Wakino, Shu ; Itoh, Hiroshi. / NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{ab338a97dc67452697fb6eec5b066b93,
title = "NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism",
abstract = "Nicotinamide N-methyltransferase (NNMT) catalyses the reaction between nicotinamide (NAM) and S-adenosylmethionine to produce 1-methylnicotinamide and S-adenosylhomocysteine. Recently, this enzyme has also been reported to modulate hepatic nutrient metabolism, but its role in the liver has not been fully elucidated. We developed transgenic mice overexpressing NNMT to elucidate its role in hepatic nutrient metabolism. When fed a high fat diet containing NAM, a precursor for nicotinamide adenine dinucleotide (NAD)+, these NNMT-overexpressing mice exhibit fatty liver deterioration following increased expression of the genes mediating fatty acid uptake and decreased very low-density lipoprotein secretion. NNMT overactivation decreased the NAD+ content in the liver and also decreased gene activity related to fatty acid oxidation by inhibiting NAD+-dependent deacetylase Sirt3 function. Moreover, the transgenic mice showed liver fibrosis, with the induction of inflammatory and fibrosis genes. Induced NNMT expression decreased the tissue methylation capacity, thereby reducing methylation of the connective tissue growth factor (CTGF) gene promoter, resulting in increased CTGF expression. These data indicate that NNMT links the NAD+ and methionine metabolic pathways and promotes liver steatosis and fibrosis. Therefore, targeting NNMT may serve as a therapeutic strategy for treating fatty liver and fibrosis.",
author = "Motoaki Komatsu and Takeshi Kanda and Hidenori Urai and Arata Kurokochi and Rina Kitahama and Shuhei Shigaki and Takashi Ono and Hideo Yukioka and Kazuhiro Hasegawa and Hirobumi Tokuyama and Hiroshi Kawabe and Shu Wakino and Hiroshi Itoh",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-26882-8",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism

AU - Komatsu, Motoaki

AU - Kanda, Takeshi

AU - Urai, Hidenori

AU - Kurokochi, Arata

AU - Kitahama, Rina

AU - Shigaki, Shuhei

AU - Ono, Takashi

AU - Yukioka, Hideo

AU - Hasegawa, Kazuhiro

AU - Tokuyama, Hirobumi

AU - Kawabe, Hiroshi

AU - Wakino, Shu

AU - Itoh, Hiroshi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Nicotinamide N-methyltransferase (NNMT) catalyses the reaction between nicotinamide (NAM) and S-adenosylmethionine to produce 1-methylnicotinamide and S-adenosylhomocysteine. Recently, this enzyme has also been reported to modulate hepatic nutrient metabolism, but its role in the liver has not been fully elucidated. We developed transgenic mice overexpressing NNMT to elucidate its role in hepatic nutrient metabolism. When fed a high fat diet containing NAM, a precursor for nicotinamide adenine dinucleotide (NAD)+, these NNMT-overexpressing mice exhibit fatty liver deterioration following increased expression of the genes mediating fatty acid uptake and decreased very low-density lipoprotein secretion. NNMT overactivation decreased the NAD+ content in the liver and also decreased gene activity related to fatty acid oxidation by inhibiting NAD+-dependent deacetylase Sirt3 function. Moreover, the transgenic mice showed liver fibrosis, with the induction of inflammatory and fibrosis genes. Induced NNMT expression decreased the tissue methylation capacity, thereby reducing methylation of the connective tissue growth factor (CTGF) gene promoter, resulting in increased CTGF expression. These data indicate that NNMT links the NAD+ and methionine metabolic pathways and promotes liver steatosis and fibrosis. Therefore, targeting NNMT may serve as a therapeutic strategy for treating fatty liver and fibrosis.

AB - Nicotinamide N-methyltransferase (NNMT) catalyses the reaction between nicotinamide (NAM) and S-adenosylmethionine to produce 1-methylnicotinamide and S-adenosylhomocysteine. Recently, this enzyme has also been reported to modulate hepatic nutrient metabolism, but its role in the liver has not been fully elucidated. We developed transgenic mice overexpressing NNMT to elucidate its role in hepatic nutrient metabolism. When fed a high fat diet containing NAM, a precursor for nicotinamide adenine dinucleotide (NAD)+, these NNMT-overexpressing mice exhibit fatty liver deterioration following increased expression of the genes mediating fatty acid uptake and decreased very low-density lipoprotein secretion. NNMT overactivation decreased the NAD+ content in the liver and also decreased gene activity related to fatty acid oxidation by inhibiting NAD+-dependent deacetylase Sirt3 function. Moreover, the transgenic mice showed liver fibrosis, with the induction of inflammatory and fibrosis genes. Induced NNMT expression decreased the tissue methylation capacity, thereby reducing methylation of the connective tissue growth factor (CTGF) gene promoter, resulting in increased CTGF expression. These data indicate that NNMT links the NAD+ and methionine metabolic pathways and promotes liver steatosis and fibrosis. Therefore, targeting NNMT may serve as a therapeutic strategy for treating fatty liver and fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=85048095522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048095522&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-26882-8

DO - 10.1038/s41598-018-26882-8

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 8637

ER -